Methylation Biosignature in Childhood Chronic Kidney Disease: the Link Among Asymmetric Dimethylarginine, Homocysteine, and Cardiovascular Disease
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 69
- 试验地点
- 1
- 主要终点
- change from baseline level of asymmetric dimethylarginine (ADMA) at 24 months
研究概览
简要总结
Chronic kidney disease (CKD) and end-stage renal disease are highly prevalent in Taiwan. Cardiovascular disease (CVD) is the most common cause of death in children with CKD. Nitric oxide (NO) deficiency links CKD and CVD. Asymmetric dimethylarginine (ADMA), a NO synthase inhibitor, its level is increased in kidney disease and cardiovascular disease and serves as a methylation biomarker.
In addition to ADMA, uremic environment, hyperhomocysteinemia (Hcy) and oxidative stress may affect DNA methylation. S-adenosylmethionine (SAM) is an important human methyl donor. S-adenosylhomocysteine (SAH) is demethylated product. Methylenetetrahydrofolate reductase (MTHFR), a folate metabolism enzyme can regulate methylation pathway.
The investigators intend to examine whether ADMA, SAM/SAH ratio, Hcy, and MTHFR gene methylation can serve as biosignature to predict CVD in children with CKD children.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 3 Years 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •chronic kidney disease stage 1-4
- •Volunteer
排除标准
- •pregnancy
- •renal transplant
- •congenital heart disease
- •not able to be adherent/complaint with study procedure
- •not volunteer
结局指标
主要结局
change from baseline level of asymmetric dimethylarginine (ADMA) at 24 months
时间窗: from the time of enrollment, every 6 months, up to 24 months
at the time of enrollment, 6 months, 12 months, 18 months, and 24 months
次要结局
- change from the baseline health-related quality of life at 24 months(from the time of enrollment, every 6 months, up to 24 months)
- change from the baseline ratio of SAM/SAH (S-adenosylmethionine /S-adenosylhomocysteine ) at 24 months(from the time of enrollment, every 6 months, up to 24 months)
- change from the baseline level of hyperhomocysteinemia (Hcy) at 24 months(from the time of enrollment, every 6 months, up to 24 months)
研究者
Tain, You-Lin
MD, PhD
Chang Gung Memorial Hospital